Johnson & Johnson (NYSE:JNJ) is Thomas Story & Son LLC's 9th Largest Position

Key Points

• Thomas Story & Son LLC increased its stake in Johnson & Johnson by 3.2% during Q1, now holding 62,911 shares worth approximately $10.43 million, making it the firm's 9th largest position.
• Johnson & Johnson's recent earnings report showed $2.77 EPS, surpassing estimates, and a revenue of $23.74 billion, indicating a 5.8% year-over-year growth.
• The company announced a quarterly dividend of $1.30, which translates to a 3.0% yield, with the payment scheduled for September 9th.

Thomas Story & Son LLC lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 62,911 shares of the company's stock after acquiring an additional 1,941 shares during the quarter. Johnson & Johnson accounts for 4.1% of Thomas Story & Son LLC's investment portfolio, making the stock its 9th largest position. Thomas Story & Son LLC's holdings in Johnson & Johnson were worth $10,433,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Elios Financial Group Inc. grew its position in shares of Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC grew its position in shares of Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after buying an additional 67 shares during the last quarter. MBA Advisors LLC grew its position in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its position in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc grew its position in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of several research reports. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Raymond James Financial lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $173.98 on Tuesday. The company has a market cap of $418.99 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $174.60. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a 50-day simple moving average of $159.63 and a 200-day simple moving average of $157.79.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.82 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.